Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Osteosarcoma × endostar protein × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Osteosarcoma 1 Bone Neoplasms 1

Interventions

Temozolomide 4 Ifosfamide 4 Gemcitabine 3 surufatinib 2 irinotecan sucrosofate 2 Vincristine 2 Nivolumab 2 Irinotecan 2 Etoposide 2 Doxorubicin 2 vactosertib 1 temsirolimus 1 talazoparib 1 silmitasertib 1 selinexor 1 pepinemab 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 pazopanib 1 liposomal doxorubicin 1 lenvatinib 1 endostar protein 1 dostarlimab 1 dinutuximab 1 copanlisib 1 apatinib 1 abemaciclib 1 Zoledronic Acid 1 X-Rays 1 Thrombopoietin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06562673 2025-12-29

IACE-OS

Shanghai 6th People's Hospital

Phase 1/2 Completed

Bone Neoplasms, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡